If you have tried MDMA, you may be eligible to enroll in this study investigating the effects of MDMA on the startle response. You will receive monetary compensation for completing the study. All involvement …
On October 15, 2019, the U.S. Food and Drug Administration (FDA) responded to MAPS with a continued clinical hold with safety concerns regarding the submitted protocol for an Expanded Access program for …
On September 18, 2019, the twentieth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara …
On September 15, 2019, MAPS responded to the U.S. Food and Drug Administration’s (FDA) continued clinical hold with Protocol A3V1 and agreed to all.
On August 28, 2019, the nineteenth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara …
On July 15, 2019, the seventeenth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara …
On July 12, 2019, MAPS received a response from the U.S. Food and Drug Administration (FDA) regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic …
In June 2019, MAPS responded to the U.S. Food and Drug Administration’s (FDA) continue clinical hold letter regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy …
On June 5, 2019, the fifteenth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara Rothbaum, …
In May 2019, the U.S. Food and Drug Administration (FDA) sent a formal response to MAPS regarding the submitted protocol for an Expanded Access program for MDMA-assisted psychotherapy for posttraumatic …
On May 1, 2019, the thirteenth participant completed experimental treatment in our ongoing study of the effect of MDMA on startle testing in healthy volunteers. Led by Principal Investigator Barbara Rothbaum, …
In April 2019, MAPS Public Benefit Corporation (MAPS PBC) sent a response to the clinical hold letter received by the U.S. Food and Drug Administration (FDA) regarding the submitted protocol for an Expanded …
